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and Benoıˆt Lengele´, MD, PhD, FRCSzObjective: During the last decade, face allotransplantation has been shown to
be a revolutionary reconstructive procedure for severe disfigurements. How-
ever, offer to patients remains limited due to lifelong immunosuppression. To
move forward in the field, a new pathway in tissue engineering is proposed.
Background: Our previously reported technique of matrix production of a
porcine auricular subunit graft has been translated to a human face model.
Methods: 5 partial and 1 total face grafts were procured from human fresh
cadavers. After arterial cannulation, the specimens were perfused using a
combined detergent/polar solvent decellularization protocol. Preservation of
vascular patency was assessed by imaging, cell and antigen removal by DNA
quantification and histology. The main extracellular matrix proteins and
associated cytokines were evaluated. Lip scaffolds were cultivated with dermal,
muscle progenitor and endothelial cells, either on discs or in a bioreactor.
Results: Decellularization was successful in all facial grafts within 12 days
revealing acellular scaffolds with full preservation of innate morphology.
Imaging demonstrated a preservation of the entire vascular tree patency.
Removal of cells and antigens was confirmed by reduction of DNA and
antigen markers negativation. Microscopic evaluation revealed preservation
of tissue structures as well as of major proteins. Seeded cells were viable and
well distributed within all scaffolds.
Conclusions: Complex acellular facial scaffolds were obtained, preservingsimultaneously a cell-friendly extracellular matrix and a perfusable vascular
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A t the dawn of the 21st century, conventional facial reconstructivetechniques, based on the use of autologous tissues, have shown
their limitations and inability to simultaneously restore the morpho-
logical identity, cosmetic appearance, and expressive function de-
voted to the human face. In 2005, the first successful facial
transplantation1,2 was applied to the highly complex three-dimen-
sional (3D) framework of the face, relying on the vascularized
composite tissue allotransplantation (VCA) principles learned from
limb transplantation.3 The success of face transplantation raised a lot
of hopes for a significant improvement of the surgical treatment of
severe disfigurement. A decade later, however, face transplantation
remains of limited clinical applications with an overall of 35 cases
reported worldwide.4 While ethical concerns have been overcome by
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Duisit et al Annals of Surgery  Volume XX, Number XX, Month 2017balance of the procedure remains questioned, because of need for a
lifelong immunosuppression (IS).6
Initially, the reluctance to accept the procedure relied mostly
on the risk of acute rejection, whereas nowadays the main concern
regarding the future of this technique is chronic rejection. Like in
other types of VCA, chronic rejection7,8 induces distal vascular
impairment, which results in a mean graft survival of 10 to 15 years.
Hence, the need to open up new therapeutic pathways arose, with 2
different strategic options: the first one is aimed at reaching the
ultimate goal of a long-term graft tolerance,9,10 the second one relies
on the de novo creation of new grafts, that will naturally be tolerated,
through the new original pathway of regenerative medicine.11
In regenerative medicine, the so-called cell seeding on scaf-
fold technology (CSST), in which cells from a patient can be grown
on extracellular matrix (ECM) scaffolds to produce functional
organs, has been previously investigated in solid organs12–16 and
limbs17 with very promising results. In a previous report,18 we
demonstrated the successful application of CSST in a porcine ear
graft model, designed as an emblematic initial experimental platform
to start face bioengineering. The so-obtained results on the auricular
facial subunit led us to draw 3 hypotheses for the present study: first,
can we extend CSST to other types of facial subunits, such as the
nose, lips, cheeks, or even a whole face? Then, can we transpose it to
a human model? And finally, can we extend the donor criteria for face
graft procurement, through the resistance of composite tissues from
cadaveric donors to biological degradation?
METHODS
Our study was conducted on 5 segmental lower face grafts
(SF-G) and 1 full face graft (FF-G), procured from fresh human
cadavers from body donation at Universite´ catholique de Louvain,
within a median delay of 50 hours (range 12–96) from death. Median
age was 82 years (range 63–96). The cadavers were stored in a cold
room at 48C until graft procurement. All the experiments were
approved by the local ethical committee.
Surgical Technique
SF-G involving the nose, lips, and cheeks subunits were
elevated as previously described19 after facial artery (FA) and vein
isolation, with the facial, mental, and infra-orbital nerves. Both FAs
were cannulated and muscles labeled (Fig. 1A–C). In case of the
FF-G, procurement was extended to the upper face, adding both
superficial temporal arteries (STA) (Fig. 1K–L).
Perfusion-decellularization Technique
All grafts were immersed in a glass jar, and the arterial
cannulas were connected to a Masterflex L/S peristaltic pump with
16G tubing (Cole Parmer, Vernon Hills, IL). Mean arterial pressure
(MAP) was recorded with a Datex-Ohmeda S/5 monitor (GE Health-
care Life Sciences, Chicago, IL). Perfusion of both FAs, keeping the
MAP below 80 mm Hg, was divided into 3 sequences, respecting
volumes load indicated for SF-G. In the first sequence, adapted from
Ott et al,12 the solution consisted of heparinized saline (15 UI/mL,
1.5 L), 10mM adenosine (A-4036, Sigma-Aldrich, St. Louis, MO);
1% SDS (70 L); deionized water (6 L); 1% Triton-X 100 (9 L); and
PBS (30 L). During the second sequence, defatting was achieved
using 2-propanol (ISO) (VWR, Radnor, PA). After a first overnight
stirring-bath (1 L), ISO was perfused in closed circuit perfusion (2 L)
for 12 hours. After a second overnight ISO stirring-bath (1 L), grafts
were rehydrated, with deionized water (1 L) and PBS perfusion
(26 L). During the third sequence, type I bovine DNAse (Sigma-
Aldrich) (25 mg/L, 1.5 L PBS) was perfused at 378C, then washed
with PBS (10 L). During all 3 steps, MAP as well as the graft were
2 | www.annalsofsurgery.com
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mucosae, fat and muscle bleaching. For FF-G, perfusion was done
alternatively in STAs and FAs.
Produced segmental (SF-ECM) and full (FF-ECM) face ECM
scaffolds were either processed for analysis or stored at 48C in PBS.
In Vitro Vascular Assessment, Mock Transplantation,
and In Vivo Reperfusion Study
SF-ECM vascular patency was assessed by fluoroscopy, ac-
quired with a Powermobil C-Arm (Siemens, Munich, Germany).
FF-ECM were injected with a barium sulfate-gel solution (40 mL), as
previously described,20 then imaged with a Senograph Essential
(GE Healthcare, Chicago, IL). To mimic transplantation, the FF-
ECM was replaced on the original donor head and images acquired
with a computed tomography (CT) scanner (Philips Healthcare,
Cleveland, OH), and analyzed using Osirix software (Pixmeo,
Bernex, Switzerland).
To assess if the innate vasculature of the scaffold would
support a physiological blood pressure, we heterotopically reper-
fused a SF-ECM graft under general anaesthesia in a porcine
recipient. Both FAs were anastomosed to abdominal aorta and the
inferior mesenteric artery. After systemic heparinization, reperfusion
was observed for 4 hours.
Tissue Sampling
SF-G and SF-ECMs were sampled for histology, quantifica-
tion of DNA and proteins, at various locations and in triplicate
(Fig. 2A).
Histology, Immunohistochemistry, and
Immunofluorescence
Samples were processed according to standard protocols,
including 5-mm-thick sectioning and staining with H&E and Mas-
son’s trichrome. Methods followed previously described protocols.21
For immunohistochemistry (IHC), sections were incubated with anti-
MHC class I antibody (1:200, ab198376, Abcam, Cambridge, UK)
and anti-CD31 (1:100, ab28364, Abcam). Nuclei were counter-
stained with hematoxylin. For immunofluorescence (IF), incubation
was performed with anticollagen IV (1:500, ab6586, Abcam), anti-
laminin (1:50, ab11575, Abcam), and nuclei were counterstained
with 40,6-diamidino-2-phenylindole (DAPI).
DNA Quantification
DNA was extracted from samples with a DNeasy kit (Qiagen,
Hilden, Germany) and quantified using the Quant-it Picrogreen
dsDNA assay kit (ThermoFischer Scientific, Waltham, MA), accord-
ing to the manufacturer’s instructions. To determine the remaining
DNA fragments size, samples were analyzed by gel electrophoresis,
as previously described.22
Quantification of ECM Proteins, Growth Factors,
and Cytokines
To understand how the decellularization process affected the
ECM and their presence, major ECM proteins, several growth
factors, and cytokines were quantified. Collagen was quantified
using a Chondrex hydroxyproline assay kit (Chondrex Inc,
Redmond, WA); Glycosaminoglycan (GAGs) content was evaluated
using the Blyscan Sulphated-GAG assay kit (Biocolor LTD,
Carrickfergus, Northern Ireland) and elastin content was quantified
using the Fast Elastin Assay kit (Biocolor), according to the man-
ufacturer’s protocols. Concentration of growth factors and cytokines
were quantified using the Bio-Plex Pro Human Chemokine 40-plex
Panel and Bio-Plex Pro TGF-b assays (Bio-Rad, Hercules, CA)
according to the manufacturer’s guidelines.
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FIGURE 1. Segmental and full face grafts per-
fusion-decellularization. A–C, Native segmen-
tal (SF-G) nose-lip face graft with its associated
vascular pedicles, in A anterior and B posterior
views. C, represents the lower lip cross section
with the associated tissue layers of skin (S), fat
(F), orbicularis ori muscle (M), and oral mucosa
(Mc). D–F, Decellularized segmental face graft
(SF-ECM) demonstrating a satisfying superficial
aspect of D the acellular skin, mucosa, fat and E
muscle stumps labelled with a nylon suture; F,
deep thickness examination of the lip, demon-
strating treatment of all layers. G and H, Fluo-
roscopy demonstrates that patency of the facial
artery (FA) and branches is preserved when
comparing G native SF-G with H produced
acellular SF-ECM vascular tree. I, Mean arterial
pressure (MAP) during the main decellulariza-
tion steps of SF-G expressed inmmHg: baseline
(T0), at the end of sodiumdodecyl sulfate (SDS)
perfusion, and after final rinsing (PBS). J, DNA
content in native (N-) and decellularized (D-)
tissues: skin, oral mucosae, fat, facial muscles,
and cartilage. Results expressed in ng/mg ECM
and native tissue (dry weight). Data presented
as mean SEM, P < 0.05,  P < 0.05,  P <
0.0001 by 2-tailed unpaired t test. K and L,
Native full-thickness face graft (FF-G), in K an-
terior and L posterior views. M, Decellulariza-
tion apparatus and graft in process. N and O,
Decellularized full-thickness face graft (FF-
ECM), exhibiting obvious skin and annexes
treatment as well as tissues on the inner side.
P, Radiogram of the barium-gel injected decel-
lularized FF-ECM; contrast injection through
superficial temporal arteries (STA) and facial
arteries (FA) demonstrates a very well preserved
vascular tree after decellularization.
Annals of Surgery  Volume XX, Number XX, Month 2017 Human Face Graft BioengineeringStatic Disc Cell-seeding
1 cm2 discs of acellular lips (Lip-ECM) obtained from SF-
ECM were sterilized with 0.1% peracetic acid (PCA). Sixteen discs
were seeded with 50  104 NIH-3T3 dermal fibroblast (Sigma-
Aldrich) and 4106 C2C12 (Sigma-Aldrich) myoblast progenitor
cell lines, placed in 24-well plates, and allowed to grow in supple-
mented Dubelcco’s Modified Eagle Medium (DMEM), changed
every 2 days. For C2C12 cells, we used 1% FBS as differen-
tiation medium. After 14 days, biopsies were either processed
 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer Health, Inc. Uaccording to standard protocols as whole-mount for Live/Dead
Cell Viability assays (ThermoFisher Scientific), prepared for
analysis with a field-emission scanning electron microscope
(JSM-7600F, Jeol, Akishima, Tokyo, Japan), or processed for H&E
staining.
Whole Lip Bioreactor Cell-seeding
Two upper Lip-ECM were procured with their artery from SF-ECM, sterilized with 0.1% peracetic acid, setup in a 500 mL
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FIGURE 2. FF-ECM mock transplantation and SF-
ECM in vivo reperfusion. A–F, Mock transplanta-
tion of the FF-ECM and angio-CT. A–C, Anterior,
lateral, and upper views of FF-ECM replaced and
sutured on the original donor head defect; preser-
vation of facial morphology in all areas, including
cartilaginous support of the nasal framework, as
well as transition with original native areas. D–F,
corresponding angio-CT views from previous pan-
el, showing the perfect anatomical and plastic
congruence of the acellular graft and its opacified
vasculature, with the underlying bone support of
the recipient. G–K, In vivo reperfusion of SF-ECM in
a porcine recipient. External view G before and H
after vascular clamp release; the general recolora-
tion is obvious, especially on the lip vermillion. I,
Internal aspect of the revascularized scaffold, with
signs of oral mucosa reperfusion and capillary
bleeding on the section lines. Similar observations
on J lip section and K nasal septum.
Duisit et al Annals of Surgery  Volume XX, Number XX, Month 2017perfusion-bioreactor and conditioned through medium perfusions for
4 hours at 378C/5% CO2 conditions (Fig. 5I, J).
C2C12 Cells
The bioreactor was filled with Dulbecco Modified Eagle Me-
dium differentiation medium supplemented with 1% FBS. 70  106
cells were collected and delivered into the scaffold by twenty 0.1 mL
4 | www.annalsofsurgery.com
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increased thereafter to 4 mL/min. After 2 weeks, the recellularized
scaffolds were examined by Live/Dead and H&E stainings.
Human Aortic Endothelial Cells (HAEC)
After immersion in Endothelial Cell Growth Medium
6MV2 (Bio-Connect, Toronto, Canada), 2510 HAEC (304-05A,
 2017 Wolters Kluwer Health, Inc. All rights reserved.
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Annals of Surgery  Volume XX, Number XX, Month 2017 Human Face Graft BioengineeringSigma-Aldrich) were slowly injected through the arterial line. A
static period was observed for 4 hours, to allow cell attachment.
Then flow was restarted at 1 mL/min for 48 hours; thereafter,
biopsies were processed for Live/Dead, H&E and CD31 IHC
stainings.
Statistical Analysis
All statistical analyses were performed using Prism 7.00
(GraphPad Software, La Jolla, CA). Values were expressed as mean
 standard error of the mean, and significance was set at P<0.05,
using 2-tailed unpaired t test.
RESULTS
Macroscopic Decellularization, Vascular Patency,
and DNA Reduction
The used perfusion method successfully and consistently
resulted in complete cell clearance of the face grafts, while preserv-
ing their ECM. Macroscopically, epidermal blistering appeared in the
first 24 hours of SDS perfusion; epidermolysis was complete and
muscle became whitish within a few days, with remaining lipidic
content; fat became completely white after the polar solvent se-
quence (Fig. 1A–F). Fluoroscopy demonstrated the patency of the
FA main axis and branches of the SF-ECM (Fig. 1G, H). During the
decellularization process, the MAP was increased during the SDS
perfusion step, associated with graft diffuse edema which resolved
after the final perfusion (Fig. 1I). This phenomenon was principally
located in the fat layer. The DNA content was significantly reduced
in all tissues, with a mean reduction of 97% (P < 0.001) in
decellularized biopsies compared with native ones (Fig. 1J). The
remaining DNA fragments size was found heterogeneous, with some
long fragments especially observed in cartilage and muscle. When
extending the process to a full-face graft (Fig. 1K–M), we also
observed a satisfying aspect in all graft tissues (Fig. 1N, O). The
arterial radiogram revealed an extremely well-preserved vasculature
(Fig. 1P).
Mock Transplantation and CT of a FF-ECM,
In Vivo Reperfusion of a SF-ECM Graft
The replacement of the produced FF-ECM on the original
donor harvesting site enhanced the quality of morphological preser-
vation of the face in all anatomical areas (Fig. 2A–C) and integration
to the native environment. The CT-scan examination of the mock
transplantation showed an excellent integration of the graft and
vessels in 3D, with a perfect plastic congruence on the underlying
facial bone support (Fig. 2D–F).
During in vivo reperfusion, the SF-ECM arteries could be
easily anastomosed to the recipient vessels. A restored flow was
immediately observed in the lips, then on the nasal septum and
graft margins and was patent for the 4-hours observation period
(Fig. 2G–K).
Cell and Antigen Clearance
H&E staining performed in all anatomical subunits did not
identify any basophilic staining indicative of cell nuclei (Fig. 3B–E).
This was confirmed by negative MHC-I antigen staining (Fig. 3F–H).
These findings indirectly indicate the cellular clearance. However, the
cartilage did retain some cells, as we reported in the porcine ear
engineering18 and in the literature23 with a negligible impact on DNA
content.
Preservation of ECM Proteins and Growth Factors
Masson’s trichrome showed a structural preservation of wholecollagen (Fig. 3J, K), and especially type IV collagen (Fig. 3L),
 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer Health, Inc. Uinvolved in basal membrane preservation, for dermal junction,
vessels, and glands. For the muscle, laminin was very well preserved,
as confirmed by laminin staining (Fig. 3M), a positive factor for
subsequent muscular regeneration.24 Regarding the major ECM
protein content (Fig. 4A), collagen was found important in all tissues,
with a high relative increase. For elastin, the reduction was signifi-
cant in all tissues with exception of fat. For the GAGs, a significant
decrease was observed in skin, mucosa, and muscle; for fat and
cartilage they were relatively well preserved.
Regarding decellularization effect on cytokines and growth
factors (Fig. 4B), we observed in skin a significant decrease of IL-8
and GM-CSF; SDF-1alpha, IL-10, TNF-alpha and IL6 did not
decrease significantly due to their high variation in the native tissues.
In mucosa, a significant decrease of all analyzed cytokines was
observed with the exception of IL-8 and IL-6, which nevertheless
showed a clear tendency to decrease. The fat presented the highest
grade of preservation, with a significant decrease of GM-CSF, IL-10,
and TNF-alpha. In facial muscles, a significant decrease of GM-CSF
and IL-10, a tendency to decrease of IL-8, TNF-alpha, and IL-6 with
partial preservation of SDF-1alpha were observed. Finally, cartilage
presented a significant decrease of all analyzed cytokines but
SDF-1alpha.
Cell Compatibility and Distribution on Discs
For both NIH-3T3 and C2C12 cell-seeded constructs showed
viability, attachment, and proliferation of the cells on the scaffold
surface in all the samples. Cells remained at the surface of the
scaffolds with a limited deep migration, relying on the passive aspect
of cell seeding and on the high density of the ECM (Fig. 5B–D). For
C2C12, cells adopted a different muscular phenotype (Fig. 5E–H).
Whole-lip Bioreactor Vascular Seeding (Fig. 5I–P)
C2C12-injected lip demonstrated cell groups at different
superficial and deep levels, mainly located in the parenchyma,
forming clusters, and infiltrating the matrix with some migration.
Cell viability was confirmed by Live/Dead staining (Fig. 5K–M).
HAEC, observed homogenously in vessels, throughout the
scaffold whole-thickness, were viable (Fig. 5N) and exhibited vas-
cular attachment. Cells with a typical endothelial morphology were
located on the vessel wall, in both large and small vessels, rather than
remaining in the lumen (Fig. 5O). CD31 staining was observed on the
vascular wall similar to normal endothelium phenotype (Fig. 5P).
Some cell clusters could be found at the border of the graft, as
vascular leakage.
DISCUSSION
This report describes matrix production from human cadaveric
face grafts. Our protocol successfully decellularized segmental and
total faces, while keeping their morphology, sustaining vascular
perfusion, and allowing cell engraftment.
Previous work by our group on the porcine ear model has
allowed scaling up to the entire face in the human model, with the
main difference of adding a polar solvent step, as described for
isolated adipose tissue decellularization.25,26 Indeed, contrary to
solid organs, adipose tissue is a true anatomical and functional
compartment in the face.27 Finally, we confirmed that deceased
donors from even several days can be used: this resistance to
degradation of composite tissues could be explained by their low
metabolic cell activity, and a high collagen content.
Growth factor preservation in matrix is a key factor, as
investigated in organ CSST.28 Our decellularization method allowed
for a partial preservation of growth factors, which were still detect-
able in skin, mucosa, fat, muscle, and cartilage. Interestingly, in
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FIGURE 3. Microscopic assessment of SF-ECM. A, The mapping for SF-ECM biopsies is defined on the subunits division of this
segmental face graft: nose (N), cheek (C), lips (L). B–D, H&E staining of the 3 different subunits, from native and decellularized
grafts, with cell removal at all levels, confirming the DNA content analysis (see Fig. 1J), with preservation of the ECM structure. B, In
the cheek, epidermis (E) and skin appendages exhibit clear cell clearance, leaving an acellular dermis (D); this anatomical location
allows amore important observation of the adipose tissue (fat, F). C, The nose allows amore specific study of the elastic cartilage (C)
tissue layer, demonstrating structural preservation after decellularization. Remaining cell nuclei can be observed in the deep layer,
but not correlated to high remaining DNA. D, In the lip, facial muscle (M) can be specifically studied and exhibits complete cell
clearance with structural preservation. E, Decellularized nerve compared with native (insert). F–H, Anti-MHC class I IHC staining
in the cheek, nose, and lip biopsies, comparing native (left) and decellularized (right) tissues, with absence of staining in the latest.
J–M, Examination of specific ECM structural proteins. J and K, Masson’s trichrome stain demonstrates collagen preservation in the
nose and lip areas. L, Anti-type IV collagen IF staining in native (left) and decellularized skin (right): the staining is positive for both
vessels, glands, and dermal basal membranes. M, Anti-laminin IF staining in native (left) and decellularized (right) facial muscles,
with evidence of its preservation in the scaffold. Scale bars represent 200mm.
Duisit et al Annals of Surgery  Volume XX, Number XX, Month 2017all the analyzed tissues, TGF-beta1 and TGF-beta3 were only
minimally decreased with a significant decrease only in mucosa.
Other detectable cytokines have a role in stem cell chemotaxis and
survival (SDF-1alpha), in differentiation and migration of monocytes
and neutrophils (GM-CSF and IL-8), and in the modulation of the
inflammatory process (TNF-alpha, IL-6, and IL-10). Although
we found some remaining long DNA fragments, discussed as a
possible negative predictive factor in the host,22,29,30 this observation
was balanced by a very small DNA matrix content, by the modulated
6 | www.annalsofsurgery.com
Copyright © 2017 Wolters Kluwer Health, Inc. Uncontent of inflammatory cytokines, and finally the negative HLA
markers in our scaffolds.
Face is a very unique anatomical and functional organ, con-
sisting in a very complex association of different tissues, which must
be uniformly treated. Further studies in facial CSST should concen-
trate on a subunit approach, as we did with the lip in the present study,
to allow an anatomical selectivity of tissue associations and a
discrimination of specific tissues: nose and ear for cartilage; lips
and eyelids, for muscle; cheeks for adipose tissue and muscle.
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FIGURE 4. Evaluation of the decellularized process on the preservation of collagen, elastin, glycosaminoglycans, growth factors,
and cytokines. A, Quantification of elastin, collagen, and GAGs in native (N-) and decellularized (D-) skin, oral mucosa, fat, muscle,
and cartilage tissue biopsies from native segmental face grafts and decellularized segmental face ECM. Elastin, even with a certain
degree of preservation, is significantly reduced in all tissues, with exception of the adipose tissue. The collagen is highly preserved,
and even demonstrates an important increase after decellularization, due to its relative gain with decrease of the other ECM
proteins. GAGs are significantly reduced in skin, mucosa, and muscle, whilst relatively preserved in the fat and cartilage tissues. B,
Cytokine concentrations of TGF-beta1, TGF-beta3, SDF1-alpha, IL-8, GM-CSF, IL-10, TNF-alpha, and IL-6 in biopsies collected from
native and decellularized tissues, analyzed by Luminex-like multiplex assay. Preservation of the analyzed cytokines ranged from
57.431.1 for TGF-beta3 to 0.40.1 for IL-8 in skin, from 71.513.9 for TGF-beta3 to 0.10.03 for IL-8 in mucosa;
from 178.315.6 for SDF-1a to 4.80.4 for IL-8 in fat; from 62.716.9 for TGF-beta3 to 2.00.4 for IL-8 in muscle and
from 38.617.3 for TGF-beta1 to 0.20.05 for IL-8 in cartilage. Data presented as mean SEM, ns¼not significant, P < 0.05,
 P< 0.01,  P< 0.001 by 2-tailed unpaired t test. The content is expressed in mg/mg dry weight for ECM proteins and in pg/mg
for cytokines.
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FIGURE 5. Acellular lip (Lip-ECM) disc culture and bioreactor recellularization after 14 days of culture. A–H, Static NIH-3T3 and
C2C12 cells seeding. A, Acellular lip discs in the 24-well plate and conditioned withmedium prior to seeding. B–D, NIH-3T3 dermal
fibroblast cell line seeding result on the acellular lip side section. B, Cells are found on the whole section, as seen on C, enlarged view
from B, with a remaining mainly at the scaffold surface (arrows). D, In some locations, a certain degree of cell migration in the
scaffold can be seen. E–H, C2C12myoblast progenitor cell seeding results. E, Live/Dead whole-mount staining revealing a majority
of living cells; C2C12 cells have taken an elongated morphology, typical of ongoing muscular differentiation. F and G, SEM
observation of the cultured discs, showing an important contact of the cells with the scaffold ECM. H, H&E observation of cells
forming proliferative conglomerates at the surface, with a limited degree of migration into the scaffold. I–P, Perfusion-recellula-
rization of a whole upper-lip acellular graft in a perfusion-bioreactor. I, Lip-ECM with the cannulated labial artery, extracted from a
segmental face scaffold. J, Perfusion-bioreactor apparatus in a CO2 incubator, with preconditioning of the lip with medium. K–M,
C2C12 cells injection seeding. K, Seeding through 20 0.1 mL injections of cells and cultured for 2 weeks. L, Live/Dead of
recellularized lip, with observation of a large proportion of living cells, organized in clusters. M, H&E examination of the cell clusters
showing signs of cell contact with the ECM. N–P, Human aortic endothelial cells (HAEC) vascular seeding and culture for 48 hours.
N, Live/Dead observation shows positivity of living cells, located in the vessels. O, H&E examination demonstrates attachment of
endothelial cells on the intimal vessel wall, with excellent endothelial morphological aspect. P, Anti-CD31 IHC staining demon-
strates positivity of the seeded cells, at all vessels calibers, from arterial pedicle to distal vessels (insert). Scale bars represent 200mm.
Duisit et al Annals of Surgery  Volume XX, Number XX, Month 2017Moreover, given the importance of the neuromuscular component in
the facial function, research on face bioengineering should also focus
on this aspect, to ultimately warrant the motility of the construct.
Restoration of face discriminative expressivity is indeed the ultimate
8 | www.annalsofsurgery.com
Copyright © 2017 Wolters Kluwer Health, Inc. Ungoal of any reconstructive procedure, especially in the lower and
midface areas. Applied to VCA in general, this technology could
result in functional developments, critical for bioengineering of other
highly complex body parts, like hands.
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Annals of Surgery  Volume XX, Number XX, Month 2017 Human Face Graft BioengineeringContrary to solid organs,31 xenotransplantation cannot be
applied to face which is species-specific, and CSST techniques must
apply to human models. Ideally, facial ECM should reproduce the
exact missing morphology of the patient, and serve as a template for
the ex novo bioengineering of the new face to implant. As current
state-of-the-art synthetic technologies32 have not yet reached this
step, due to the unfeasibility of replicating the complexity of the
matrisome and 3D framework of the innate human ECM, human
organs are being proposed as source of ECM. Since the first report on
discarded human kidneys as a platform for organ bioengineering and
regeneration,11 numerous studies have corroborated the idea that
ECM scaffolds obtained from the decellularization of human organs
may represent a valuable template for organ biofabrication15,28,33–39
Importantly, these studies have shown that partial regeneration of the
cellular compartment of the 3D innate ECM can be obtained, but to
an extent that it is still not compatible with physiological functional
needs. Our experience confirms these findings, as our cells were not
able to diffusely migrate within the 3D framework of the ECM. As
stigmatized by the experiences with kidney bioengineering, major
physical barriers remain in CSST that limit in vitro recellularization
of acellular scaffolds, and numerous are the obstacles that must be
investigated to effectively advance this strategy for regenerative
medicine.40 While the regeneration of the endothelium should be
considered the sine qua non condition for bedside application,
research should aim at identifying alternative regenerative strategies
to solve the high complexity of recellularizing acellular ECM
scaffolds of composite grafts, possibly using the recipient as its
own bioreactor, as intelligently suggested by others.41
In the history of surgery, solid organ transplantation preceded
VCA. This sequence also occurred for tissue engineering. The two
domains, however, are now merging in an unprecedented synergetic
effort in the whole field of transplantation surgery.42
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DISCUSSANTS
Michael Olausson (Gothenburg, Sweden):
First, I would like to thank for the opportunity to discuss this
interesting paper on tissue engineering of face transplants. Ever since
the landmark paper of Doris Taylor in Nature Medicine in 2008, a
growing number of laboratories have tried to use decellularizartion
techniques, followed by recellularization with stemcells, to regrow
the organ with autologous recipient cells. So far, with limited
success, ending in a clinical transplantation, has been seen. It is
my belief that is wise to use nature’s own matrix in recreating life.
The alternative, using an artificial matrix, and build something that
took 5 billion years to create, seems even more difficult.
First, regarding the decellularization process. You used SDS
and Triton-X 100. Could you elaborate how you can be sure that all
detergents are removed after its use as well as explaining why DNAse
was not used?
Second, regarding the ECM proteins. How large proportion of
the original matrix proteins was preserved and how do you think this
could affect the recreation of the organ? Did you use proteomics
using MS-LC techniques to see if any proteins disappeared?
Third, regarding the migration of the cells. You have sug-
gested that a dynamic seeding through the vasculature would ensure
the migration. Could you please enlighten us on the density of cells in
the bioreactor vascular recellularized whole-lip in comparison to the
same tissue before decellularization?
Finally, I want to congratulate you on an interesting paper.
Response from Jerome Duisit (Brussels, Belgium):
Thank you for the comments. For the decellularization, actu-
ally we know that SDS is efficient to treat the matrix but is difficult to
remove: That’s why we used additionally used Triton-X for this
purpose. We could use for example mass spectrometry, to have an
estimation of the residual SDS inside the matrix. But performing an
important PBS solution rinsing, with an equivalent volume of
perfused SDS, as we did, has been proven efficient in the literature.
Our best proof was the survival of the cells. When we will go further
into refining our method, we will certainly have to perform mass
spectrometry. I think SDS is the best experimental solution for
composite tissues. About the DNAse, we actually used it. For the
remaining DNA, we assessed it by quantification and the length of
fragments. We used the enzyme in this study to obtain the lowest
DNA value that could be obtained. However, it shouldn’t be manda-
tory when dealing only with in vitro studies. It will be more important
to consider for in vivo studies, because of the residual DNA possible
adverse events on immune response.
For the study of structural ECM proteins, we first used
histological qualitative techniques, as well as quantification with
colometric assays for collagen, elastin, and GAGs. For the ECM-
associated proteins, growth factors, and cytokines, we used quanti-
tative multiplex assays. The structural proteins were very well
preserved, especially collagen above 100%. This relative increase
is explained by the removal of cells, and the decrease of GAGs and
elastin. So, the relative collagen content in a same biopsy volume
10 | www.annalsofsurgery.com
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2/3rd of the GAGs and a preservation of half of elastin in the
cartilage. For the cytokines, what was more important was to see
that it didn’t disappear totally and the types of proteins remaining: If
you want to orientate stem cells differentiation, you will prefer SDF-
1alpha or TGF-beta content to be high in your scaffold. If you target
proteins that are involved into in vivo immune reactions, you want
more TNF-alpha or IL-10. For the moment, the most important was
the preservation of the structural proteins, associated to the mechan-
ical properties.
About the migration of cells: we first tried to obtain a uniform
distribution of cells through the scaffold, as assessed by different
observers, for the same biopsies at different locations. For the
endothelium, we looked for the diameters the seeded vessels, and
the continuity of the cells layer. We didn’t try for the moment to
regenerate the media with smooth muscle cells, or with another type,
like pericytes, which are going to be critical in vivo to limit the
problem of edema formation. This is a big matter in vasculature of
composite tissues, because they are less robust compared with the
solid organs, with a very delicate and fragile vascular bed, and so
very sensitive to an increase of perfusion pressure. We also
observed an early edema associated to the adipose tissue, which
retains a lot the fluid extravasation. It’s more during a next step that
we will try to repopulate the thickness of the vessels, and especially
the artery, and try to see how we can regenerate a functional distal
micro circulation.
Henri Bismuth (Villejuif, France):
First of all, I compliment you for this impressive presentation.
I think that you are modest when you say that the face is not a vital
organ. It is a vital organ and you and another group showed that the
patients that are not well repaired, are socially excluded, have a poor
professional life and sometimes in despair commit suicide. So, it is a
vital organ and I think that you are right to work on the ways to
increase the number of grafts. My question is about the other
modality to obtain the scaffold. You spoke about human graft, using
decellularization process in order to obtain scaffold. What about
bioprinting, which is used as you know for plain organs such as the
liver. I imagine there is special difficulty for the nerves, which are of
course very important for the face, or for the vessels. So, I would like
to know if there is some attempt of bioprinting of the face in
order to have the scaffold which could be easier than human graft
decellularized?
Response from Jerome Duisit (Brussels, Belgium):
Thank you for the question, Professor Bismuth. Actually, it’s
very interesting because our presentation’s title was extended to ‘‘the
matrix of identity.’’ We meant the restoration of a biological identity,
while replacing donor cells by the recipient’s ones. But for our
disfigured patients, we will also have to restore their lost morpho-
logical identity and provide a customized reconstruction. It is going
to be achieved through bioprinting for sure. Decellularization/
recellularization technology is a step, and we will make it available
for patients; but we have already to consider bioprinting. For the
moment, this technology is available for simple and small tissues,
due to a lack of vasculature and an access to it: thus, current scaffolds
are limited to a few cm3, because relying on a passive penetration of
the nutrients. What we are trying to do for the moment is to extract
the 3D structure information from the decellularized scaffolds we
produce. We have to understand first the Nature’s genius before
trying to reproduce it. Indeed, the strategy in bioprinting is more
about materials, but the fine structure of the tissues is missing. The
efforts will also need the unify microscopic features with gross
anatomy. It’s a very emerging field we have here for the future,
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Annals of Surgery  Volume XX, Number XX, Month 2017 Human Face Graft Bioengineeringbut for the moment what does exist in bioprinting remains quite
rudimentary. In the examples of the ear and nose, printed versions
remain homogeneous, with only 1 tissue layer, and lacking a vascular
tree: the face or even a subunit are by definition composite: the only
nose contains multiple tissues like mucosa, skin, cartilage, vessels,
nerves: this is impossible to reproduce by bioprinting for the
moment. What we try to learn is how to deal with complex scaffolds,
identify the patient’s cells reservoir, and how to bring the cells into
the matrix: from decellularized origin now, and later on from
synthesis.
Inne Borel-Rinkes (Utrecht, The Netherlands):
Very nice paper. Compliments and congratulations. I would
like to elaborate a little bit more on the different types of cells, you
told us that you see cells as I understand correctly with different
methods and techniques to get the cells where you want them to be.
What is, for instance, your experience, what is the source of the cells?
How do you isolate them, how do you keep them alive and particu-
larly if you’ve seeded them? What’s the longevity and what’s the
vitality of the cells? What percentage of cells actually do take and are
capable of staying there?
Response from Jerome Duisit (Brussels, Belgium):
Thank you for the question. Well, actually we’ve been trying
different types of cells, with different seeding routes, in a sterile
perfusion-bioreactor. You can perform graft injections, seed through
the vasculature, or topically for the skin. This is the difficulty with
composite tissues: We have different compartments to treat at
once, with different accesses. We have been working mainly with 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2017 Wolters Kluwer Health, Inc. Umesenchymal stem cells. The main difficulty was to obtain an
important density of cells within the scaffold: Even a human half-
lip represents much more volume than a heart of a rat (in reference to
the seminal tissue engineering work from Ott et al). In this study for
example, we have been seeding up to 16 millions of cells, which
finally was low. But, what we screened was more the quality of the
spreading, than the density obtained. Badylak in his last Nature’s
editorial, supported the strategy of a combined approach: seeding
in vitro the minimum cells and rely on the body to complete the
scaffold regeneration, which is actually regenerative medicine.
Bringing both together is very likely to be a long-term strategy,
relying first on a vascular regeneration, with an access allowing
replantation. In a previous paper in Annals of Surgery, our idea was to
see if the stem cells were able to differentiate on the matrix, driven by
the ECM: if you remember the cross-section of our lip scaffold, you
could see that all tissue layers are joined together. With the vascular
route, you can’t select where in the different tissues the cells will be
going. So, we will have to rely on the stem cells, like IPS, matrix-
orientated differentiation. We know that’s not particularly limiting
for the moment, but will be needed to validate this aspect, critical for
composite tissues. For the cells spreading, we are currently adapting
seeding parameters: If the cells should remain inside the vascular
tree, then you have to perform a slow perfusion, to stick to the vessels
only. If you want the cells to spread into the tissue, seeding will be
done with a lot of pressure, to force the cells to go in the extravascular
space. Our main initial mistakes were a too weak or too strong
perfusion. ‘‘Fine tuning’’ is a next step, but we have already all the
elements to start new researches. We hope that other groups will join
the effort in this new field: active collaborations will be critical in
composite tissue engineering.cell lines, because we targeted a critical number of cells, as well aswww.annalsofsurgery.com | 11
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